Accelerate Diagnostics, Inc. (AXDX) recently announced the completion of the pre-clinical trial of its WAVE system. The WAVE pre-clinical trial showed strong performance, along with strong instrument reliability and assay reportability.With the latest success, the company is confident about WAVE product design and the system's capabilities. This, in turn, should help Accelerate Diagnostics to move ahead with a clinical trial and further commercialize the WAVE system.About the WAVE SystemThe WAVE system is d ...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - President and CEO David Patience - Chief Financial Officer Conference Call Participants Andrew Brackmann - William Blair Operator Good day. And welcome to the Accelerate Diagnostics Incorporated Second Quarter 2024 Results Conference Call. All participants will be in a listen-only mode. After today’s presentation, there will be ...

Accelerate Diagnostics (AXDX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $2.36 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 9.09%. A quarter ago, it was expected that this maker of systems that diagnose drug-resistant infections would post a loss of $0.72 per share when it actually produced a loss of $0.88, delivering a surprise of -22.2 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1072256 (State ...

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024."During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVETM System and Gram-Negative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success," commented Jack Phillips, President and CEO of Accelerate Diagnostics, Inc. "Additionally, we were able to ...

Exhibit 99.1 Accelerate Diagnostics Reports Second Quarter 2024 Financial Results TUCSON, Ariz., August 8, 2024 -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the second quarter ended June 30, 2024. During the quarter we completed our pre-clinical trial demonstrating strong analytical performance of our WAVE System and GramNegative Positive Blood Culture (PBC) assay. We are pleased to announce our pre-clinical trial was a success." commented Jack Phillips, President and ...

TUCSON, Ariz., Aug. 8, 2024 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced that management will host a conference call today, Thursday, August 8, 2024, at 4:30 p.m. Eastern Time to review 2024 second quarter results.To listen to the audio webcast online, visit ir.axdx.com. A replay of the audio webcast will be available for 30 days.To listen by phone, dial +1.877.883.0383 and enter the Elite Entry Number: 9884567. International participants may dial +1.412.902.6506. Please dial in 10- ...

A dead cat bounce is when a falling stock sees a short-term recovery, but is ultimately likely to head lower. It comes from the idea that “even a dead cat will bounce if it falls from a great height.” The stock market does not move in a straight line, and there are many ups and downs whichever way a stock moves. Thus, investors would be best served understanding which stocks are more akin to dead cats than recovery bids, particularly in this market.Many stocks with horrible fundamentals could plunge much fu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-31822 ACCELERATE DIAGNOSTICS, INC. (Exact name of registrant as specified in its charter) Delaware 84-1072256 (Stat ...

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q1 2024 Earnings Conference Call May 8, 2024 4:30 PM ET Company Participants Laura Pierson - Investor Relations Officer Jack Phillips - Chief Executive Officer, President & Director David Patience - Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer Conference Call Participants Dustin Scaringe - William Blair Operator Good day, and welcome to the Accelerate Diagnostics Incorporated. First Quarter 2024 Results Conference Call. All pa ...